Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
about
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.What constitutes optimal neurohumoral antagonism in chronic heart failure?
P2860
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@ast
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@en
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@nl
type
label
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@ast
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@en
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@nl
prefLabel
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@ast
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@en
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@nl
P2860
P356
P1476
Dual Angiotensin Receptor and ...... nderstanding the New PARADIGM.
@en
P2093
Matthew P Lillyblad
P2860
P304
P356
10.1177/1060028015593093
P407
P577
2015-07-14T00:00:00Z